Biotechnology

Clinical trial
#Biotechnology #Chemotherapy #Clinical trials #Immunotherapy

Data shows significant results in cancer-associated fibrosis models 

Redx, a clinical-stage biotechnology company focused on discovering and developing novel, small molecule, targeted therapeutics for the treatment of cancer and fibrotic disease, announced preclinical data for its lead fibrosis asset, RXC007, and the Discodin Domain Receptor (DDR)1/2 discovery programme.   The data were from preclinical models of… Read More

#News

#Age-related diseases (ARDs) #Ageing #AI #Biotechnology #Business #Clinical trials #mRNA

Podcast: The impact of technology on drug discovery

This is the latest episode of the free DDW narrated podcast, “The impact of technology on drug discovery”. It covers two articles written for Volume 23, Issue 2 – Spring 2022 of DDW. They are called “Talking Tech” and “Rejuvenation biotech: Can… Read More

#News

#BioIndustry Association #Biotechnology #Clarivate #Funding #Investment #Private investment #UK

UK biotech sector raised £295 million in first quarter of 2023

The first quarter of 2023 has seen deal flow continue for UK life science and biotech companies at all stages of development, new data from the UK BioIndustry Association and Clarivate shows. As global macro-economic headwinds, suppressed public markets and political uncertainty weighed on investor confidence, venture investment remained steady,… Read More

#Business & Investment #Market Reports #News

#Biologics #Biology #Biotechnology #Drug development #Therapeutics

Next-generation pipeline for treating mast cell driven diseases 

Granular Therapeutics, a UK-based biotech company specialising in precision biologic therapies for treating mast cell driven disorders, announced clinical candidate selection for its lead programme which has demonstrated promising results in initial preclinical studies.  Granular Therapeutics has now commenced proof-of-concept (POC) and IND-enabling studies as it prepares… Read More

#News

Pancreatic cancer concept
#Biotechnology #Cancer research #Drug development #Drug discovery #Gene therapy #Oncology

How this biotech is looking to collaboration to treat pancreatic cancer

DDW Editor Reece Armstrong speaks to Howard Davis, CEO of clinical stage oncology company, Akamis Bio, about its work in developing a gene therapy to treat pancreatic cancer.    In February this year, Akamis Bio announced an expansion of its ongoing partnership with the Parker Institute for Cancer Immunotherapy (PICI) to include… Read More

#Exclusive Content

#Biotechnology #cryo-microscopy #Drug targets #Pharmacology

Salipro successfully extracts PANX1 membrane protein

Salipro Biotech, in collaboration with AstraZeneca, has published data from a study which describes a novel method to directly extract membrane proteins from cells into lipid Salipro nanoparticles, enabling structure-function analysis using surface plasmon resonance (SPR) and cryo-electron microscopy (cryo-EM) for challenging drug targets. The scientists extracted and… Read More

#News

#Biopharmaceuticals #Biotechnology #Epidemiology #Infectious diseases #Novel candidates

Destiny Pharma publishes landmark XF-73 clinical data  

Destiny Pharma, a UK-based clinical stage biotechnology company focused on the development of novel medicines to prevent life threatening infections, has published landmark XF-73 clinical data in the US peer reviewed journal Infection Control & Hospital Epidemiology.    The paper was published by Dr. Julie Mangino… Read More

#News

#Biotechnology #Cancer research #Clinical research #Innovation passport #MHRA #Solid tumours #T-Cells

Uveal melanoma drug granted MHRA Innovation Passport 

iOnctura, a clinical stage biotechnology company developing breakthrough therapies for patients suffering with cancer, has been awarded the innovative medicine designation, the Innovation Passport, for roginolisib, for the treatment of metastatic uveal melanoma by the Medicines & Healthcare products Regulatory Agency (MHRA).  Roginolisib is a first-in-class, non-ATP-competitive,… Read More

#News

Covid-19
#Biotechnology #Covid-19 #Immunology / Virology & Vaccines

Developing next generation pan-SARS-CoV-2 vaccines 

SpyBiotech, a UK-based biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, has received a grant of $4,094,561 from the Bill & Melinda Gates Foundation to further develop its novel SpyVector platform.   This project will harness SpyBio’s ‘plug… Read More

#Covid-19 #News

siRNA
#Biotechnology #Dermatology #Funding #Immuno-dermatology #siRNA

Is this a novel approach to immuno-dermatology? 

Aldena Therapeutics, a biotech company that is pioneering siRNA-based therapies for dermatological indications, has updated its immuno-dermatology pipeline, appointed a Scientific Advisory Board (SAB), and announced $30 million financing by Medicxi.  Pipeline  Under the leadership of Thibaud Portal, CEO of Aldena, the company’s goal is to develop advanced, long-lasting treatments… Read More

#Business & Investment #News

Haematology
#Biotechnology #Cancer research #Clinical research #Solid tumours #T-Cells

Research reveals the unique biological features of roginolisib 

iOnctura, a clinical stage biotechnology company developing cancer therapies, has published non-clinical research on roginolisib in the AACR journal Cancer Research Communications. Roginolisib is a first-in-class, non-ATP-competitive, allosteric modulator of PI3Kd which prevents tumour proliferation and breaks immune tolerance in patients with solid and haematological… Read More

#Cancer Research #News

Downing Street, London, UK
#BioIndustry Association #Biotechnology #Research & development #UK budget #UK government

Industry calls on UK Government to support biotech SMEs

Ahead of the UK’s Spring Budget, the UK BioIndustry Association (BIA) is calling on the Treasury to provide additional support through the R&D tax relief scheme to R&D intensive SMEs. These companies are the most at risk from the R&D tax relief rate cut announced at… Read More

#News

#Biotechnology #Drug development #Neurodegenerative disorders #Neuroscience #Seed funding

€28M for neurodegenerative disease treatments

Teitur Trophics, a biotech company developing new treatments for patients suffering from neurodegenerative diseases, has complete a €28M Series A financing.   The financing was co-led by Sunstone Life Science Ventures and Sound Bioventures, with participation from new investors, Industrifonden, Innovestor’s Life Science Fund and P53 Invest. The proceeds will enable… Read More

#Business & Investment #News

#Biotechnology #Cancer #Fibrotic disease #Monotherapy #Small molecul #Therapeutics

Topline data from Phase II monotherapy module

Redx, a clinical-stage biotechnology company focused on discovering and developing novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease, has shared topline monotherapy data from the biliary tract cancer (BTC) module of the RXC004 PORCUPINE2 Phase II clinical trial programme. RXC004 is an… Read More

#News

DNA biopharma image
#Biopharmaceutical #Biotechnology #Drug discovery #Sustainability

Future trends: biopharma to outpace small molecule drug development  

Gary Connors, Partner at business consulting company Oliver Wight EAME looks at some of the most important factors that will affect the pharmaceutical industry going forward.   We advise all our clients to make assumptions and think about scenarios that could affect their business at least five years in advance. Read More

#Exclusive Content

Social media
#AI / data analytics / healthtech / informatics #Biotechnology #Business #Social media

Biotech goes social: Tips for effective social media marketing

Kristina Tatiossian, PhD, founder of Arkitekt Agency, looks at how biotech companies are currently using social media and provides a five-step guide for how to make the most of this ubiquitous marketing tool. Biotechnology organisations can leverage social media for a variety of purposes, from boosting awareness and increasing engagement,… Read More

#Business & Investment #Exclusive Content